Source:http://linkedlifedata.com/resource/pubmed/id/19027877
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2008-12-23
|
pubmed:abstractText |
Although inhibitors of the enzymatic hydrolysis of the endocannabinoid 2-arachidonoylglycerol are available, they are either rather weak in vitro (IC(50)>30 microM) or their selectivity towards other proteins of the endocannabinoid system has not been tested. Here we describe the synthesis and activity in vitro and in vivo of a tetrahydrolipstatin analogue, OMDM169, as a potent inhibitor of 2-AG hydrolysis, capable of enhancing 2-AG levels and of exerting analgesic activity via indirect activation of cannabinoid receptors. OMDM169 exhibited 0.13 microM<IC(50)<0.41 microM towards 2-AG hydrolysing activities in COS-7 cells and rat cerebellum, and inhibited (IC(50)=0.89 microM) the human recombinant MAGL, whilst being inactive (K(i)>10 microM) at human CB(1) and CB(2) receptors. However, OMDM169 shared with tetrahydrolipstatin the capability of inhibiting the human pancreatic lipase (IC(50)=0.6 microM). OMDM169 inhibited fatty acid amide hydrolase and diacylglycerol lipase only at higher concentrations (IC(50)=3.0 and 2.8 microM, respectively), and, accordingly, it increased by approximately 1.6-fold the levels of 2-AG, but not anandamide, in intact ionomycin-stimulated N18TG2 neuroblastoma cells. Acute intraperitoneal (i.p.) administration of OMDM169 to mice inhibited the second phase of the formalin-induced nocifensive response with an IC(50) of approximately 2.5 mg/kg, and concomitantly elevated 2-AG, but not anandamide, levels in the ipsilateral paw of formalin-treated mice. The antinociceptive effect of OMDM169 was antagonized by antagonists of CB(1) and CB(2) receptors, AM251 and AM630, respectively (1 mg/kg, i.p.). OMDM69 might represent a template for the development of selective and even more potent inhibitors of 2-AG hydrolysis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2-arachidonylglycerol,
http://linkedlifedata.com/resource/pubmed/chemical/Analgesics,
http://linkedlifedata.com/resource/pubmed/chemical/Arachidonic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Formamides,
http://linkedlifedata.com/resource/pubmed/chemical/Glycerides,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoprotein Lipase,
http://linkedlifedata.com/resource/pubmed/chemical/Monoacylglycerol Lipases,
http://linkedlifedata.com/resource/pubmed/chemical/Propiolactone
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0006-3002
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
1791
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
53-60
|
pubmed:meshHeading |
pubmed-meshheading:19027877-Analgesics,
pubmed-meshheading:19027877-Animals,
pubmed-meshheading:19027877-Arachidonic Acids,
pubmed-meshheading:19027877-COS Cells,
pubmed-meshheading:19027877-Cercopithecus aethiops,
pubmed-meshheading:19027877-Enzyme Inhibitors,
pubmed-meshheading:19027877-Formamides,
pubmed-meshheading:19027877-Glycerides,
pubmed-meshheading:19027877-Humans,
pubmed-meshheading:19027877-Hydrolysis,
pubmed-meshheading:19027877-Inhibitory Concentration 50,
pubmed-meshheading:19027877-Lipoprotein Lipase,
pubmed-meshheading:19027877-Mice,
pubmed-meshheading:19027877-Monoacylglycerol Lipases,
pubmed-meshheading:19027877-Propiolactone,
pubmed-meshheading:19027877-Rats
|
pubmed:year |
2009
|
pubmed:articleTitle |
Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo.
|
pubmed:affiliation |
Institute of Biomolecular Chemistry, C.N.R., Pozzuoli (Naples), Italy.
|
pubmed:publicationType |
Journal Article
|